Pyxis Oncology Q2 net loss $25.6M, cash $207M; stops PYX-202, prioritizes two lead programs

Pyxis Oncology, Inc.

2022-Q2 EPS reported -$1.76

Cash $207M as of Aug 15, 2022; expected to fund operations through second half of 2024.
Q2 net loss $25.6M ($0.79/sh) vs $8.1M ($5.54/sh) in 2021; R&D expense $17.2M (from $3.2M).
Prioritizes PYX-201 (anti-EDB ADC) and PYX-106 (anti-Siglec-15 mAb) for IND filings in H2 2022.
Ceases development of PYX-202 (anti-DLK1 ADC) after toxicology data; pauses PYX-203 and PYX-102.
Appoints Dr. Rachel Humphrey to Board; receives option grant for 236,220 shares at $2.91.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Rachel Humphrey

Director

PYXS · Pyxis Oncology, Inc.

Effective: 2022-08-11
Filed: August 15, 2022, 7:59 PM ET

On August 11, 2022, Pyxis Oncology, Inc. appointed Rachel Humphrey, M.D., to its Board of Directors and to serve on the Board’s Nominating and Corporate Governance Committee and Compensation Committee.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Rachel Humphrey was appointed as Director at Pyxis Oncology, Inc..

Action: appointed
Role: Director

Exact text from the filing

On August 11, 2022, Pyxis Oncology, Inc. appointed Rachel Humphrey, M.D., to its Board of Directors and to serve on the Board’s Nominating and Corporate Governance Committee and Compensation Committee.

View on SEC.gov

Pyxis Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-017220

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.